Regulation - Pharmaceutical, Cell Therapeutics

Filter

Popular Filters

Non-Hodgkin lymphoma treatment Pixuvri given market access in France

19-08-2013

USA-based Cell Therapeutics (Nasdaq: CTIC) has been granted market access in France for its aggressive…

Cell TherapeuticsEuropeOncologyPharmaceuticalPixuvriRegulation

Germany's G-BA issues final assessment for Cell Thera's Pixuvri

21-05-2013

USA-based Cell Therapeutics (Nasdaq: CTIC) says that Germany's Federal Joint Committee (G-BA) has issued…

BiotechnologyCell TherapeuticsEuropeOncologyPharmaceuticalPixuvriPricingRegulation

Positive NICE recommendation for Novartis' Lucentis, but not for Cell Thera's Pixuvri

11-04-2013

There was good news for Swiss drug major Novartis (NOVN: VX) this morning, when UK drugs watchdog the…

BiotechnologyCell TherapeuticsEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPixuvriPricingRegulation

Germany's IQWiG finds no added benefit for Komboglyze or for Pixuvri

04-03-2013

In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

AstraZenecaBiotechnologyBristol-Myers SquibbCell TherapeuticsDiabetesEuropeKomboglyzemetforminOncologyPharmaceuticalPixuvriPricingRegulationsaxagliptin

Cell Therapeutics' Pixuvri cleared in EU for NHL

14-05-2012

US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) last week received conditional marketing authorization…

BiotechnologyCell TherapeuticsEuropeOncologyPharmaceuticalPixuvriRegulation

EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri

20-02-2012

Finalizing its review on orlistat-containing medicines and the possible risk of severe liver injuries,…

AlliBayerBiotechnologyCardio-vascularCell TherapeuticsEuropeGlaxoSmithKlineMetabolicsOncologyorlistatPharmaceuticalPixuvriRegulationRocheTrasylolXenical

FDA advisory to review Cell Thera’s re-submitted pixantrone NDA

03-01-2012

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review Cell Therapeutics’…

Cell TherapeuticsNorth AmericaOncologyPharmaceuticalpixantronePixuvriRegulation

Back to top